717 related articles for article (PubMed ID: 20664274)
21. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
22. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma.
Bousquet J; Cabrera P; Berkman N; Buhl R; Holgate S; Wenzel S; Fox H; Hedgecock S; Blogg M; Cioppa GD
Allergy; 2005 Mar; 60(3):302-8. PubMed ID: 15679714
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of omalizumab in a patient with severe asthma, low serum IgE level, and lack of sensitized allergens induced by oral steroid therapy: the usefulness of impulse oscillation for assessment of omalizumab therapy.
Matsuno O; Komori C; Hang Y; Matsumoto T; Minamoto S
J Asthma; 2012 Oct; 49(8):839-42. PubMed ID: 22920591
[TBL] [Abstract][Full Text] [Related]
24. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
Holgate ST; Djukanović R; Casale T; Bousquet J
Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
26. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
[TBL] [Abstract][Full Text] [Related]
27. [Anti-IgE therapy in persistent allergic asthma].
Skiepko R; Zietkowski Z; Tomasiak-Łozowska MM; Bodzenta-Łukaszyk A
Przegl Lek; 2009; 66(3):141-4. PubMed ID: 19689039
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of omalizumab in non-allergic severe asthma.
Domingo C; Pomares X; Angril N; Rudi N; Amengual MJ; Mirapeix RM
J Biol Regul Homeost Agents; 2013; 27(1):45-53. PubMed ID: 23489686
[TBL] [Abstract][Full Text] [Related]
29. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma.
Hoshino M; Ohtawa J
Respiration; 2012; 83(6):520-8. PubMed ID: 22236804
[TBL] [Abstract][Full Text] [Related]
30. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.
Riccio AM; Dal Negro RW; Micheletto C; De Ferrari L; Folli C; Chiappori A; Canonica GW
Int J Immunopathol Pharmacol; 2012; 25(2):475-84. PubMed ID: 22697079
[TBL] [Abstract][Full Text] [Related]
31. Comparison of exhaled nitric oxide measurement with conventional tests in steroid-naive asthma patients.
Zietkowski Z; Bodzenta-Lukaszyk A; Tomasiak MM; Skiepko R; Szmitkowski M
J Investig Allergol Clin Immunol; 2006; 16(4):239-46. PubMed ID: 16889281
[TBL] [Abstract][Full Text] [Related]
32. [Pneumology. Anti-IgE antibodies in the treatment of asthma].
Leuenberger P; Sauty A; Rochat T
Rev Med Suisse; 2007 Jan; 3(93):56-9. PubMed ID: 17354662
[TBL] [Abstract][Full Text] [Related]
33. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma.
Bousquet J; Siergiejko Z; Swiebocka E; Humbert M; Rabe KF; Smith N; Leo J; Peckitt C; Maykut R; Peachey G
Allergy; 2011 May; 66(5):671-8. PubMed ID: 21255035
[TBL] [Abstract][Full Text] [Related]
34. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
[TBL] [Abstract][Full Text] [Related]
35. Effect of nasal steroid treatment on airway inflammation determined by exhaled nitric oxide in allergic schoolchildren with perennial rhinitis and asthma.
Pedroletti C; Lundahl J; Alving K; Hedlin G
Pediatr Allergy Immunol; 2008 May; 19(3):219-26. PubMed ID: 18399898
[TBL] [Abstract][Full Text] [Related]
36. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
[TBL] [Abstract][Full Text] [Related]
37. The effect of treatment with montelukast on levels of serum interleukin-10, eosinophil cationic protein, blood eosinophil counts, and clinical parameters in children with asthma.
Yüksel B; Aydemir C; Ustündag G; Eldeş N; Kutsal E; Can M; Demirtaş S; Tomaç N
Turk J Pediatr; 2009; 51(5):460-5. PubMed ID: 20112601
[TBL] [Abstract][Full Text] [Related]
38. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
[TBL] [Abstract][Full Text] [Related]
39. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab.
Nowak D
Respir Med; 2006 Nov; 100(11):1907-17. PubMed ID: 16949266
[TBL] [Abstract][Full Text] [Related]
40. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
